By Julia Karow
Beckman Coulter said last week that it has combined Agencourt Bioscience and recently acquired Cogenics to form Beckman Coulter Genomics.
The new Beckman unit, which offers genomic services such as sequencing, sample prep, genotyping, gene expression, and biological efficiency and safety testing, is headquartered in Beverly, Mass., where Agencourt is located.
The company offers next-generation sequencing services on the 454 GS FLX, Applied Biosystems SOLiD, and Illumina Genome Analyzer platforms, as well as Sanger sequencing.
It also supports "all levels of regulatory compliance," including Clinical Laboratory Improvement Amendments, according to a statement from Beckman.
Beckman Coulter announced its acquisition of Cogenics from Clinical Data, which closed this spring, in April and said at the time that Cogenics would add more services, a wider geographic reach, and a CLIA-certified lab to its genomics business (see In Sequence 4/7/2009).
Cogenics had facilities in Texas, North Carolina, France, the UK, and Germany, combining former operations of Genaissance, Lark, Icoria, Genome Express, and Epidauros.